Quantitative analysis of biomarker expression can help define mechanism of action for targeted therapeutics and assess their safety and efficacy.
Plasma Biomarker Services
Plasma biomarkers can help you identify disease conditions as well as monitor progression and response to therapy. In collaboration with Rules-Based Medicine (RBM), Charles River offers Multi-Analyte Profiles (MAPs) for comprehensive biomarker assessment.
Multi-Analyte Profiles (MAPs) are high-density, quantitative immunoassay panels for laboratory animals that allow variations in biomarker patterns to be identified. MAPs provide a comprehensive evaluation of the protein expression patterns indicative of a response to disease, drugs, and the environment. They make it possible to accurately and precisely measure biomarkers of infectious disease, autoimmunity, and cardiovascular risk, as well as hormones, cytokines/chemokines, acute-phase reactants, and other blood components. By comparing samples of experimental subjects with controls, relevant biomarker patterns emerge. These patterns are critical to applications such as drug safety and efficacy, disease diagnosis, and disease modeling.
For the most current listing of analytes and pricing, please contact RBM at 1.866.RBM.MAPS.
Tissue Biomarker Services
To further characterize your models following the in vivo portion of your study, immunohistopathology, quantitative PCR-based expression testing and in situ hybridization can determine effects on key cellular and molecular processes, such as gene and protein expression, cell proliferation, cell death, or angiogenesis.